Piramal Pharma Solutions (PPS), a contract development and manufacturing organisation (CDMO) announced investments of USD 55 million across its sites in North America and Asia to expand its API manufacturing capabilities and capacities.
A part of USD 55 million investment will go into new multi-purpose plants, with over 270kL of total capacity, to support the current pipeline of approximately 80 late stage programs that PPS is currently assisting its partners with at various global sites, a company statement said.
PPS will also expand its potency footprint at its plant in Riverview, Michigan, while augmenting early development capabilities out of Ennore in India through additions of GMP kilo labs and a pilot plant.
To serve its European biotech customers better, PPS will add early development capabilities in both, drug substance and drug product, out of its Morpeth, UK facility, it said.
The company, part of Piramal Enterprises Ltd. (PEL), will also expand support functions such as analytical capabilities, R&D infrastructure, automation and IT systems at all API sites through this investment.
"With these investments, we can now support the commercialisation of our pipeline of over 80 programs that are at Phase II or beyond, while allowing us additional capacity for future partnerships, PPS CEO Vivek Sharma said.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)